Harmine Plus GLP-1 Drug Safely Grows Human Beta Cells in Living Mice
Combining harmine (a DYRK1A inhibitor) with exendin-4 (a GLP-1 drug) safely expanded human beta cell mass in a mouse transplant model.
Quick Facts
What This Study Found
Harmine plus exendin-4 combination therapy safely increased human beta cell mass in vivo in a mouse xenograft system without causing harmful proliferation.
Key Numbers
537 million people globally have diabetes. No current diabetes drugs increase beta cell numbers. The combination used harmine (DYRK1A inhibitor) and exendin-4 (GLP-1R agonist).
How They Did This
In vivo mouse xenograft study using transplanted human beta cells, testing harmine (DYRK1A inhibitor) combined with exendin-4 (GLP-1R agonist).
Why This Research Matters
537 million people worldwide have diabetes, and beta cell loss is a core problem. A drug combination that safely expands beta cells could fundamentally change diabetes treatment.
The Bigger Picture
Beta cell loss is a core problem in both type 1 and type 2 diabetes. If a drug combination can safely regrow beta cells, it could fundamentally change diabetes from a managed disease to a potentially reversible one.
What This Study Doesn't Tell Us
This was done in mice with transplanted human cells, not in human patients. Safety and efficacy in humans remain to be demonstrated.
Questions This Raises
- ?Would this combination work without transplanting cells first?
- ?Is the beta cell expansion durable after stopping treatment?
Trust & Context
- Key Stat:
- No current drug grows beta cells Among all diabetes medications in use, none actually increases the number of insulin-producing beta cells — this combination may be the first
- Evidence Grade:
- Rated moderate: in vivo demonstration using human cells in mice, stronger than cell culture alone, but still requires human clinical testing.
- Study Age:
- Published in 2024. Represents a significant advance in the quest to restore beta cell mass in diabetes.
- Original Title:
- Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system.
- Published In:
- Science translational medicine, 16(755), eadg3456 (2024)
- Authors:
- Rosselot, Carolina, Li, Yansui, Wang, Peng(2), Alvarsson, Alexandra, Beliard, Kara, Lu, Geming, Kang, Randy, Li, Rosemary, Liu, Hongtao, Gillespie, Virginia, Tzavaras, Nikolaos, Kumar, Kunal, DeVita, Robert J, Stewart, Andrew F, Stanley, Sarah A, Garcia-Ocaña, Adolfo
- Database ID:
- RPEP-09171
Evidence Hierarchy
Frequently Asked Questions
Can we grow new insulin-producing cells?
This study shows a drug combination (harmine + GLP-1 drug) can safely expand human beta cells in mice — a first step toward potentially restoring insulin production.
Why is beta cell growth important?
Both type 1 and type 2 diabetes involve loss of beta cells. If we could regrow them, we might be able to restore natural insulin production.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09171APA
Rosselot, Carolina; Li, Yansui; Wang, Peng; Alvarsson, Alexandra; Beliard, Kara; Lu, Geming; Kang, Randy; Li, Rosemary; Liu, Hongtao; Gillespie, Virginia; Tzavaras, Nikolaos; Kumar, Kunal; DeVita, Robert J; Stewart, Andrew F; Stanley, Sarah A; Garcia-Ocaña, Adolfo. (2024). Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system.. Science translational medicine, 16(755), eadg3456. https://doi.org/10.1126/scitranslmed.adg3456
MLA
Rosselot, Carolina, et al. "Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system.." Science translational medicine, 2024. https://doi.org/10.1126/scitranslmed.adg3456
RethinkPeptides
RethinkPeptides Research Database. "Harmine and exendin-4 combination therapy safely expands hum..." RPEP-09171. Retrieved from https://rethinkpeptides.com/research/rosselot-2024-harmine-and-exendin4-combination
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.